Novartis and its Sandoz unit made history on 6 March, gaining the first approval of a biosimilar in the US – Zarxio (filgrastim-sndz).
Novartis and its Sandoz unit made history on 6 March, gaining the first approval of a biosimilar in the US – Zarxio (filgrastim-sndz).
“Dozens of organizations representing consumers, seniors, payers, pharmacists, purchasers, pharmacy benefit managers, labor unions, retail pharmacies, managed care pharmacies and...
The US firm was already looking to compete in ulcerative colitis, but now expands its ambitions by moving into rheumatoid arthritis as well.
Wales-based group launches with $140m series A.
CEO Ben Zeskind said all options are on the table after atebimetinib showed impressive results in pancreatic cancer.
